IONIS ANGPTL3LRx - Ionis Pharmaceuticals

Drug Profile

IONIS ANGPTL3LRx - Ionis Pharmaceuticals

Alternative Names: AKCEA-ANGPTL3-LRX; IONIS-ANGPTL3-LRX; ISIS-703802

Latest Information Update: 30 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Akcea Therapeutics; Ionis Pharmaceuticals
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action ANGPTL3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia; Hyperlipoproteinaemia type I; Hypertriglyceridaemia; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Phase I/II Hyperlipoproteinaemia type IIa

Most Recent Events

  • 02 May 2018 Akcea Therapeutics in collaboration with Ionis Pharmaceuticals plans a phase II trial for Lipodystrophy in May 2018 , (NCT03514420)
  • 12 Apr 2018 Phase-II clinical trials in Hypercholesterolaemia in Canada (SC) (NCT03455777)
  • 14 Mar 2018 Akcea Therapeutics and Ionis Pharmaceuticals plans a phase II trial for Hypercholesterolemia in March 2018 (NCT03455777)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top